Skip to Content

IQVIA Holdings Inc IQV

Morningstar Rating
$217.46 +1.95 (0.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Narrow-Moat IQVIA Benefits From Strong Clinical Trial Outsourcing Demand; Long-Term Outlook Positive

IQVIA (formerly QuintilesIMS) is the result of the merger of Quintiles, a leading late-stage contract research organization, and IMS Health, a dominant player in life sciences data and analytics. The combined company has become a leader among CROs and in the life sciences data and analytics industry. Further, as a result of the merger, the company leads in real-world evidence, in which data from sources such as patient records or medical claims can be used to create clinical evidence for regulatory approval.

Price vs Fair Value

IQV is trading at a 199% premium.
Price
$217.46
Fair Value
$214.00
Uncertainty
Medium
1-Star Price
$873.70
5-Star Price
$798.00
Economic Moat
Pgnpdn
Capital Allocation
Vjdjnyvy

Bulls Say, Bears Say

Bulls

IQVIA’s leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.

Bears

The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IQV is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$215.51
Day Range
$215.57220.48
52-Week Range
$167.42261.73
Bid/Ask
$209.15 / $253.49
Market Cap
$39.62 Bil
Volume/Avg
1.2 Mil / 972,082

Key Statistics

Price/Earnings (Normalized)
20.93
Price/Sales
2.65
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
2.20%

Company Profile

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
87,000

Competitors

Valuation

Metric
IQV
MEDP
ICLR
Price/Earnings (Normalized)
20.9340.4923.19
Price/Book Value
6.1918.322.78
Price/Sales
2.656.443.19
Price/Cash Flow
16.8135.6019.68
Price/Earnings
IQV
MEDP
ICLR

Financial Strength

Metric
IQV
MEDP
ICLR
Quick Ratio
0.760.591.16
Current Ratio
0.860.641.21
Interest Coverage
3.12688.873.37
Quick Ratio
IQV
MEDP
ICLR

Profitability

Metric
IQV
MEDP
ICLR
Return on Assets (Normalized)
7.28%21.26%4.85%
Return on Equity (Normalized)
31.85%67.47%9.19%
Return on Invested Capital (Normalized)
12.78%49.10%8.41%
Return on Assets
IQV
MEDP
ICLR
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
JzlltqnkkTbdl$219.8 Bil
Danaher Corp
DHR
PsnrcgqhqFrqxgz$193.5 Bil
IDEXX Laboratories Inc
IDXX
GmnklmywsMcdrcsq$42.0 Bil
Agilent Technologies Inc
A
ClnktmngQftjz$38.5 Bil
Mettler-Toledo International Inc
MTD
BtlkqwbgHgmnhv$31.2 Bil
Icon PLC
ICLR
PjbkwdyFnxxpt$26.2 Bil
Waters Corp
WAT
RfndfmljcvRmsg$17.8 Bil
Illumina Inc
ILMN
SdbchfzmfXfrfyl$17.3 Bil
Labcorp Holdings Inc
LH
LpmbkrncZgbvxkm$16.5 Bil

Sponsor Center